Beigene, Ltd. ((ONC)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Beigene, Ltd. (ONC) is conducting a Phase 1 clinical study titled A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer. The study aims to evaluate the safety and effectiveness of BGB-21447, a Bcl-2 inhibitor, in combination with fulvestrant and potentially BGB-43395, for treating HR+/HER2- metastatic breast cancer, which represents a significant portion of breast cancer cases.
The study is testing BGB-21447, an oral Bcl-2 inhibitor, alongside fulvestrant, an estrogen receptor blocker, and BGB-43395, a CDK4 inhibitor. These drugs aim to disrupt cancer cell survival pathways and improve treatment outcomes for patients with HR+/HER2- metastatic breast cancer.
This interventional study is non-randomized and follows a sequential intervention model without masking. Its primary purpose is treatment-focused, assessing the safety and preliminary antitumor activity of the drug combinations.
The study began on February 4, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on June 23, 2025, indicating ongoing recruitment and study progress.
This clinical update could influence Beigene’s stock performance positively, as successful outcomes may enhance their competitive position in the oncology market. Investors should watch for further developments, as the study’s progress could impact market dynamics, especially in the breast cancer treatment sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.